A NAT2 genetic test estimates how quickly a person is likely to acetylate isoniazid, an important medicine used in treatment regimens for tuberculosis disease and tuberculosis preventive treatment. Results are usually translated into rapid, intermediate, or slow acetylator status. Slow acetylators tend to have higher isoniazid exposure at the same dose and may have a greater risk of liver injury or neurologic adverse effects. Rapid acetylators may have lower exposure, which can raise concern about inadequate drug concentrations in some settings. The test is clinically relevant, but it does not provide a complete dosing plan by itself. Tuberculosis treatment depends on whether infection or active disease is present, drug susceptibility, body weight, age, liver health, other medicines, adherence, and the full multidrug regimen. Genotype-guided dosing remains an evolving practice rather than a universal standard, so a result should be interpreted by a tuberculosis specialist or pharmacist familiar with local protocols.
- NAT2 testing predicts isoniazid acetylation phenotype, not whether a person has tuberculosis.
- Slow acetylators generally have higher isoniazid exposure and greater toxicity concern.
- Rapid acetylators may have lower exposure, but genotype does not prove treatment failure.
- No patient should change an isoniazid dose or multidrug TB regimen independently.
- Liver symptoms, adherence, drug susceptibility, and clinical monitoring remain essential for every phenotype.
Table of Contents
- What NAT2 testing measures
- How isoniazid is used in tuberculosis care
- Understanding rapid, intermediate, and slow acetylator results
- What NAT2 results may change in practice
- Toxicity monitoring and warning signs
- Limits of the test and reasons results can differ
- Questions for the treatment team
What NAT2 testing measures
NAT2 is the gene that encodes N-acetyltransferase 2, an enzyme expressed mainly in the liver and intestine. The enzyme helps process isoniazid and several other compounds through acetylation. Common inherited variants alter enzyme activity. A person receives one NAT2 allele from each biological parent, and the combination can be translated into a predicted acetylator phenotype.
The test usually uses blood, saliva, or a cheek swab. Because it examines inherited DNA, the genotype normally remains the same throughout life. A valid clinical result generally does not need to be repeated unless the first assay was incomplete, the report is unavailable, or a newer test covers variants that were missed.
NAT2 reports may list star alleles such as *4, *5, *6, *7, *12, or *13. Historically, *4 has often been treated as a rapid-function reference allele, while several *5, *6, and *7 suballeles are associated with reduced activity. The two detected alleles form a diplotype, which the laboratory converts to an acetylator category. The precise assignment can depend on which variants were tested and the nomenclature system used.
Some laboratories report rapid, intermediate, and slow acetylator. Others use terms such as rapid metabolizer, intermediate metabolizer, and poor metabolizer. Older literature may combine rapid and intermediate groups or use “fast acetylator.” A few research approaches identify an ultra-slow subgroup based on particular reduced-function combinations. These labels are not always interchangeable, so the report’s allele table and interpretation are more informative than the category alone.
The result predicts average isoniazid handling, not an exact blood concentration. Actual exposure also depends on dose, body size, formulation, food timing, absorption, liver function, kidney function, age, pregnancy, interacting medicines, and adherence. Therapeutic drug monitoring measures drug concentrations directly and may be useful in selected patients even when a genotype is known.
NAT2 testing also does not test the bacterium. Drug-resistance testing examines Mycobacterium tuberculosis and is essential when active disease is suspected or confirmed. A person can be a slow acetylator and still have isoniazid-resistant TB, or a rapid acetylator and have fully susceptible TB. Human pharmacogenetics and bacterial resistance answer different questions.
How isoniazid is used in tuberculosis care
Isoniazid is used in two broad settings: treatment of tuberculosis disease and treatment of tuberculosis infection to prevent future disease. The clinical goals and accompanying medicines differ, so a NAT2 result must be interpreted within the correct setting.
For drug-susceptible active TB disease, isoniazid is ordinarily part of a multidrug regimen. Common regimens also include rifampin or rifapentine and may include pyrazinamide, ethambutol, and moxifloxacin depending on the regimen and patient. Multiple active drugs are necessary to cure disease, reduce transmission, and prevent emergence of resistance. Altering only isoniazid without considering the full regimen can undermine treatment.
For tuberculosis preventive treatment, several options are available. Some contain isoniazid with rifapentine or rifampicin for a shorter period, while others use daily isoniazid alone for a longer period. Selection depends on age, pregnancy, HIV therapy, drug interactions, exposure history, presumed susceptibility of the source case, availability, and national guidance. A rifamycin-based alternative may be preferred in many situations because shorter regimens can improve completion and reduce overall hepatotoxicity, but interactions can make them unsuitable for some patients.
Before preventive therapy begins, active TB disease must be ruled out. Giving one or two drugs intended for prevention to someone with unrecognized active disease can lead to inadequate treatment and resistance. Symptoms, examination, chest imaging, and microbiologic testing are used as appropriate. NAT2 testing cannot make this distinction.
Isoniazid is generally given according to weight and schedule. Daily and intermittent regimens use different doses, and pediatric dosing differs from adult dosing. Food can reduce absorption, but instructions may be individualized when gastrointestinal tolerance is a problem. The treatment team should provide a written regimen that includes each medicine, dose, frequency, anticipated duration, and what to do after a missed dose.
Pyridoxine, or vitamin B6, is often prescribed with isoniazid for people at higher risk of peripheral neuropathy, including those who are pregnant, breastfeeding, living with HIV, affected by diabetes, malnutrition, alcohol use disorder, chronic kidney disease, or advanced age. Pyridoxine reduces neurologic risk; it does not prevent isoniazid-related liver injury and does not correct excessive drug exposure caused by slow acetylation.
Understanding rapid, intermediate, and slow acetylator results
The categories describe relative enzyme activity and expected exposure at a given dose. They are probabilistic, not absolute.
| Predicted phenotype | Expected isoniazid pattern | Main clinical concern |
|---|---|---|
| Rapid acetylator | Faster clearance and lower average exposure | Subtherapeutic exposure in some patients, especially when other risk factors for low concentrations are present |
| Intermediate acetylator | Exposure generally between rapid and slow groups | Standard dosing is often used, but individual variability remains substantial |
| Slow acetylator | Slower clearance and higher average exposure | Greater risk of concentration-related toxicity, particularly liver injury and peripheral neuropathy |
Slow acetylator
A slow result means both alleles are predicted to confer reduced NAT2 activity under the laboratory’s classification. Isoniazid tends to remain in the body longer, producing higher area-under-the-curve exposure and often a longer half-life. Across many studies, slow acetylator status has been associated with increased risk of anti-tuberculosis drug-induced liver injury. The association is meaningful but not deterministic: most slow acetylators do not develop severe hepatitis, and liver injury can occur in other phenotypes.
Metabolism is more complex than simply “slow equals toxic metabolite accumulation.” NAT2 participates in more than one step, and other enzymes such as amidases and CYP2E1 influence hydrazine-related pathways. The net clinical observation—higher isoniazid exposure and more toxicity in many slow-acetylator cohorts—is stronger than any overly simplified pathway diagram.
A slow result may prompt a treatment team to consider closer symptom review, more frequent liver testing in a high-risk patient, therapeutic drug monitoring, or a locally approved genotype-guided dose. It should never prompt a patient to cut tablets independently. An excessively low dose could compromise sterilizing activity, especially in active disease.
Intermediate acetylator
An intermediate result usually reflects one higher-function and one reduced-function allele. Average exposure is between the rapid and slow groups, but the distributions overlap. Many standard protocols use the conventional weight-based dose for intermediate acetylators. Research models sometimes propose a distinct dose, yet there is no single internationally accepted NAT2-specific dose schedule for every TB regimen and population.
The intermediate label is particularly dependent on assay interpretation. Some older studies classified two groups rather than three, placing intermediate patients with rapid acetylators. When reading a study or report, confirm how phenotype groups were defined before applying its conclusions.
Rapid acetylator
A rapid result predicts relatively high NAT2 activity and faster isoniazid clearance. Lower concentrations may matter when a patient also has malabsorption, low adherence, severe illness, HIV, diabetes, high body weight, or other pharmacokinetic factors. Some studies link rapid acetylation with delayed culture conversion, early treatment failure, or acquired resistance when exposure is inadequate, but genotype alone cannot predict these outcomes.
A rapid result is not an automatic instruction to increase the dose. Higher dosing may improve target attainment but can still cause toxicity, and the optimal exposure target differs according to disease site and regimen. Drug susceptibility, clinical response, microbiology, and measured concentrations may be more useful than genotype alone when treatment appears ineffective.
What NAT2 results may change in practice
NAT2-guided isoniazid dosing has been tested in clinical trials and pharmacokinetic studies. One influential randomized trial used lower isoniazid doses for slow acetylators, standard doses for intermediate acetylators, and higher doses for rapid acetylators. It reported fewer liver injuries in slow acetylators and fewer early failures in rapid acetylators under the guided strategy. Later studies and models have supported the biological rationale but have not produced a universally adopted protocol.
This distinction matters. A gene–drug association can be well supported while the best implementation strategy remains unsettled. National TB programs must balance toxicity prevention, microbiologic efficacy, simplicity, cost, laboratory turnaround time, and the danger of dosing errors. Evidence generated in one ancestry group, weight range, or six-month regimen may not transfer directly to a different population or a four-month regimen.
As of current practice, major TB guidance generally does not require routine NAT2 testing before isoniazid. Some centers, research programs, and precision-medicine services use it selectively. A result is most likely to influence care when:
- the laboratory report provides a validated phenotype and a locally approved dosing recommendation;
- the patient has a history of isoniazid toxicity or a strong reason to anticipate high exposure;
- therapeutic drug monitoring is unavailable or is being used together with genotype;
- treatment response is unexpectedly slow despite verified adherence and susceptible organisms;
- a specialist is managing a complex case, such as central nervous system TB, malabsorption, severe comorbidity, or recurrent drug intolerance.
Even when a genotype-guided dose is used, all other drugs in the regimen remain important. Rifampin and pyrazinamide can also cause liver injury, and rifamycins have extensive drug interactions. If liver enzymes rise during multidrug therapy, the genotype cannot identify the responsible medicine with certainty. Management may require stopping several hepatotoxic drugs, evaluating alternative causes, and reintroducing medicines in a controlled sequence.
NAT2 results can also inform counseling. A slow acetylator can be told why early symptom reporting is especially important. A rapid acetylator can understand why adherence and response monitoring matter. The result should reduce uncertainty, not create fear or false reassurance.
Toxicity monitoring and warning signs
Isoniazid can cause asymptomatic liver-enzyme elevation, clinically apparent hepatitis, and rarely severe liver failure. Risk is influenced by age, alcohol use, chronic viral hepatitis, baseline liver disease, pregnancy and the early postpartum period, malnutrition, HIV, interacting or hepatotoxic medicines, and the other drugs in the TB regimen. NAT2 phenotype is one risk factor among many.
Baseline liver tests are often obtained for patients with risk factors and for those receiving multidrug treatment. The need and frequency of repeat tests depend on the regimen, symptoms, local program, and baseline condition. Monthly clinical review is a minimum expectation in many TB programs. More frequent laboratory monitoring may be appropriate for a slow acetylator with additional liver risks, but normal tests do not replace symptom education.
Contact the treatment team promptly for unexplained loss of appetite, persistent nausea or vomiting, marked fatigue, right upper abdominal pain, dark or brown urine, pale stools, fever, or yellowing of the skin or eyes. These can signal hepatitis. Patients are often instructed to stop TB medicines and seek urgent assessment when significant liver symptoms occur, but the exact action plan should be provided in advance because stopping an incomplete subset of a multidrug regimen can be dangerous.
Tingling, burning, numbness, or pain in the hands and feet may indicate peripheral neuropathy. Risk increases with nutritional deficiency, diabetes, alcohol use, kidney disease, pregnancy, HIV, and inadequate pyridoxine. Dizziness, seizures, confusion, or severe weakness require urgent assessment. Slow acetylation may increase exposure, but neurologic symptoms can occur in any phenotype.
Other adverse effects may come from companion drugs: vision changes with ethambutol, severe rash from several agents, bleeding or major interactions with rifamycins, and joint symptoms or hepatotoxicity with pyrazinamide. A NAT2 report should not narrow attention so much that these other hazards are missed.
Adherence is equally important. Missing doses, taking only selected drugs, or repeatedly interrupting therapy can lead to failure, relapse, ongoing transmission, and resistance. Side effects should be reported rather than managed by unsupervised dose omission. TB programs can provide directly observed therapy, video-supported therapy, transportation, medication organization, and other adherence support.
Limits of the test and reasons results can differ
NAT2 is highly polymorphic. A targeted panel detects only the variants it was designed to test. If a person carries a rare or ancestry-enriched allele outside the panel, the laboratory may assign the wrong star allele or phenotype. Sequencing covers more variation but can identify variants whose function is uncertain.
Different laboratories may use different allele definitions, reference transcripts, phenotype rules, and terminology. NAT2 nomenclature has also evolved. A report that says “slow” should include the detected variants and diplotype so another laboratory or specialist can reassess it if standards change.
Ancestry influences allele frequencies but should not be used as a substitute for testing. Slow-acetylator genotypes are common in some European, African, Middle Eastern, and South Asian populations, while rapid alleles are more frequent in parts of East Asia and the Americas. Each broad group contains substantial diversity, and self-identified race does not reliably predict an individual result.
Genotype explains only part of pharmacokinetic variability. Age, sex, body composition, liver status, nutrition, HIV, diabetes, gastrointestinal absorption, formulation quality, and adherence all affect concentrations. Rifampin can alter metabolic pathways, and severe disease can change drug disposition. Therapeutic drug monitoring therefore measures something genotype cannot: the concentration achieved in that patient on the actual regimen.
The test does not predict all isoniazid adverse effects. Immune-mediated reactions, rash, fever, hematologic effects, and rare events involve other mechanisms. It also does not determine susceptibility to rifampin, pyrazinamide, ethambutol, or rifapentine toxicity.
Direct-to-consumer results require caution. Raw data may include one or two NAT2 variants but lack the full set needed for a reliable star-allele call. Strand orientation can reverse letter notation, and online phenotype calculators can use outdated definitions. Clinical dosing decisions should use a validated laboratory result interpreted by a qualified professional.
Finally, the most important limitation is the absence of a single global, regimen-independent dosing rule. Research doses should not be copied into clinical care without considering national guidance and expert supervision. A useful report should clearly distinguish established phenotype information from investigational dose suggestions.
Questions for the treatment team
A NAT2 result is most useful when it leads to a specific, documented plan. Consider asking:
- Which alleles and variants were tested? Confirm that the panel is validated for the patient’s ancestry and that the phenotype assignment is clear.
- Is this active TB disease or preventive treatment? The regimen, urgency, and consequences of underdosing differ.
- Is the organism susceptible to isoniazid? For active disease, review molecular and culture-based susceptibility results when available.
- Does this clinic use a validated NAT2-guided protocol? Ask whether the dose recommendation comes from national guidance, an institutional protocol, or research evidence.
- Would therapeutic drug monitoring help? It may be useful when absorption, adherence, response, or exposure is uncertain.
- Which liver tests will be checked and when? The plan should reflect genotype plus age, alcohol use, viral hepatitis, pregnancy, liver disease, and companion drugs.
- Should pyridoxine be prescribed? Clarify the dose and recognize that it protects nerves, not the liver.
- What symptoms require stopping medicines or urgent review? Obtain exact instructions and an after-hours contact.
- How will response be measured? Active disease requires clinical and microbiologic follow-up; preventive treatment requires adherence and toxicity monitoring.
Bring a complete list of prescription medicines, nonprescription products, supplements, and alcohol use. Rifamycins can interact with hormonal contraception, anticoagulants, transplant medicines, HIV therapy, methadone, antiseizure drugs, and many other treatments. Interaction management may determine the regimen more strongly than NAT2.
Do not interpret a slow result as proof that isoniazid is unsafe. With appropriate selection, dosing, counseling, and monitoring, many slow acetylators complete treatment successfully. Do not interpret a rapid result as proof that standard therapy will fail. Most treatment outcomes depend on the combined regimen, bacterial susceptibility, adherence, and adequate follow-up.
The safest conclusion is balanced: NAT2 genotype provides real information about expected isoniazid exposure, but it is one component of tuberculosis precision care. Its value comes from integrating it with clinical risk, microbiology, measured response, and expert management—not from treating the genetic category as a standalone prescription.
Keep a copy of the complete laboratory report rather than only the phenotype label. The allele call, testing method, date, and laboratory comments may be needed if treatment continues in another health system or if interpretation standards change. The written TB treatment record should separately document the diagnosis, susceptibility results, doses, dates, interruptions, adverse reactions, and completion status. Together, these records provide far more useful future guidance than a brief note stating only “slow acetylator.”
References
- WHO consolidated guidelines on tuberculosis Module 1: prevention – tuberculosis preventive treatment, second edition 2024 (Guideline)
- Treatment for Drug-Susceptible Tuberculosis Disease 2025 (Clinical Guidance)
- Adverse Events During TB Treatment 2025 (Clinical Guidance)
- Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 genotype-guided dosing in tuberculosis treatment 2024 (Clinical Study)
- Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis 2021 (Pharmacokinetic Study)
- NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy 2013 (Randomized Trial)
Disclaimer
This article is for general educational purposes and does not replace medical advice from a tuberculosis clinician or public health program. Isoniazid and companion TB medicines should never be started, stopped, or dose-adjusted solely from a genetic result without expert supervision. Suspected active tuberculosis, significant adverse effects, or treatment interruption requires prompt clinical assessment.
